[go: up one dir, main page]

BRPI0411127A - composição de matéria para modulação de resposta imuno num sujeito a um antìgeno alvo e respectivos método de modulação, processo de produção de células de apresentação de antìgeno e método de tratamento e/ou profilaxia de doença ou condição associada à presença de antìgeno alvo de interesse - Google Patents

composição de matéria para modulação de resposta imuno num sujeito a um antìgeno alvo e respectivos método de modulação, processo de produção de células de apresentação de antìgeno e método de tratamento e/ou profilaxia de doença ou condição associada à presença de antìgeno alvo de interesse

Info

Publication number
BRPI0411127A
BRPI0411127A BRPI0411127-3A BRPI0411127A BRPI0411127A BR PI0411127 A BRPI0411127 A BR PI0411127A BR PI0411127 A BRPI0411127 A BR PI0411127A BR PI0411127 A BRPI0411127 A BR PI0411127A
Authority
BR
Brazil
Prior art keywords
antigen
subject
immune response
modulation
peptides
Prior art date
Application number
BRPI0411127-3A
Other languages
English (en)
Inventor
Stephen John Kent
Original Assignee
Univ Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003902875A external-priority patent/AU2003902875A0/en
Priority claimed from AU2004901589A external-priority patent/AU2004901589A0/en
Application filed by Univ Melbourne filed Critical Univ Melbourne
Publication of BRPI0411127A publication Critical patent/BRPI0411127A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"COMPOSIçãO DE MATéRIA PARA MODULAçãO DE RESPOSTA IMUNO NUM SUJEITO A UM ANTìGENO ALVO E RESPECTIVOS MéTODO DE MODULAçãO, PROCESSO DE PRODUçãO DE CéLULAS DE APRESENTAçãO DE ANTìGENO E MéTODO DE TRATAMENTO E/OU PROFILAXIA DE DOENçA OU CONDIçãO ASSOCIADA à PRESENçA DE ANTìGENO ALVO DE INTERESSE". A presente invenção relaciona-se com o uso de pelo menos um conjunto de peptídios em composições e métodos de modulação da resposta imuno a um ou mais antígenos de polipeptídios. Em certas modalidades, as seqüências de um conjunto respectivo de peptídios são derivadas na integralidade ou em parte de um único antígeno de polipeptídios. Os peptídios individuais de um conjunto respectivo de peptídios compreendem diferentes partes de uma seqüência de aminoácidos correspondente a um antígeno de polipeptídios único e exibem identidade parcial ou similaridade de seqüências com pelo menos outro peptídio do mesmo conjunto de peptídios. A invenção também se estende a métodos de uso desses peptídios numa faixa de aplicações preventivas, de diagnose e terapêuticas. Adicionalmente, a invenção relaciona-se com o uso de células de apresentação de antígenos não cultivados ou seus precursores, que não foram sujeitos a condições de ativação e que tenham sido contatados com um antígeno, em métodos e composições de formulação da resposta imuno num recipiente daquelas células.
BRPI0411127-3A 2003-06-10 2004-06-10 composição de matéria para modulação de resposta imuno num sujeito a um antìgeno alvo e respectivos método de modulação, processo de produção de células de apresentação de antìgeno e método de tratamento e/ou profilaxia de doença ou condição associada à presença de antìgeno alvo de interesse BRPI0411127A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003902875A AU2003902875A0 (en) 2003-06-10 2003-06-10 Immunomodulating compositions, uses therefor and processes for their production
AU2004901589A AU2004901589A0 (en) 2004-03-25 Immunomodulating compositions, uses therefor and processes for their production
PCT/AU2004/000775 WO2004108753A1 (en) 2003-06-10 2004-06-10 Immunomodulating compositions, uses therefor and processes for their production

Publications (1)

Publication Number Publication Date
BRPI0411127A true BRPI0411127A (pt) 2006-05-23

Family

ID=33512072

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411127-3A BRPI0411127A (pt) 2003-06-10 2004-06-10 composição de matéria para modulação de resposta imuno num sujeito a um antìgeno alvo e respectivos método de modulação, processo de produção de células de apresentação de antìgeno e método de tratamento e/ou profilaxia de doença ou condição associada à presença de antìgeno alvo de interesse

Country Status (7)

Country Link
US (1) US20070248584A1 (pt)
EP (2) EP1638993A4 (pt)
JP (2) JP2007537975A (pt)
BR (1) BRPI0411127A (pt)
CA (1) CA2528727A1 (pt)
NZ (1) NZ544011A (pt)
WO (1) WO2004108753A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
US7495071B2 (en) * 2004-07-14 2009-02-24 Biospectrum, Inc. Antiproliferative peptides and antibodies for their detection
JP4507080B2 (ja) * 2004-07-30 2010-07-21 東亞合成株式会社 抗菌ペプチド及びその利用
FR2874612A1 (fr) * 2004-08-27 2006-03-03 Commissariat Energie Atomique Epitotes t cd4+ du vih restreints a hla-dp4 et leurs applications
US7381705B2 (en) * 2004-09-29 2008-06-03 The Administrators Of The Tulane Educational Fund Inhibitors of hepatitis C virus
BRPI0504117A (pt) * 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
EP1931699A2 (en) * 2005-09-29 2008-06-18 The Scripps Research Institute Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
TW200837075A (en) * 2007-01-10 2008-09-16 Scripps Research Inst Antiviral peptides
WO2009030872A1 (en) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Materials and methods for the treatment of hepatitis c
WO2009033726A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of cart (55-102), optionally in combination with tuftsin, as a therapeutic agent
WO2009055005A2 (en) 2007-10-23 2009-04-30 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
ES2574988T3 (es) 2008-10-06 2016-06-23 Yissum Research Development Company Of The Herbrew University Of Jerusalem Ltd. Péptidos derivados de estimulantes de la VIH-1 integrasa que interfieren con la proteína Rev-integrasa
EP2411043B1 (en) * 2009-03-23 2013-07-31 PIN Pharma, Inc. Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
CN105131112A (zh) 2009-08-29 2015-12-09 Abbvie公司 治疗用dll4结合蛋白
RU2605928C2 (ru) * 2010-03-02 2016-12-27 Эббви Инк. Терапевтические dll4-связывающие белки
DK2898890T3 (da) 2010-03-31 2019-11-25 Stabilitech Biopharma Ltd Stabilisering af viruspartikler
BR112012025047A2 (pt) 2010-03-31 2016-06-21 Stabilitech Ltd formulações líquidas estabilizadas
NZ586074A (en) * 2010-06-10 2013-07-26 Auckland Uniservices Ltd LCLRP peptides, constructs and uses thereof
WO2012078116A1 (en) * 2010-12-10 2012-06-14 Agency For Science, Technology And Research Immunogenic chikungunya virus peptides
KR101281098B1 (ko) * 2011-06-30 2013-07-02 주식회사 녹십자 Ｂ형 간염 바이러스 표면 항원상의 에피토프 및 이의 용도
GB201117233D0 (en) * 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
EP2620446A1 (en) * 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
US10188710B2 (en) * 2013-11-04 2019-01-29 Rhode Island Council On Postsecondary Education Regulatory T cell epitope and hepatitis C virus homolog
WO2015130488A2 (en) * 2014-02-28 2015-09-03 Immunotope, Inc. Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection
EP3122881A4 (en) * 2014-03-25 2017-11-15 Duke University Mosaic hiv-1 sequences and uses thereof
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
ES2946697T3 (es) 2014-09-10 2023-07-24 Miltenyi Biotec Bv & Co Kg Una población celular para su uso en el tratamiento de cáncer
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL284985B2 (en) 2015-02-18 2023-03-01 Enlivex Therapeutics R& D Ltd Combined immunotherapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
JP6803339B2 (ja) * 2015-04-21 2020-12-23 エンリヴェックス セラピューティクス リミテッド 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
WO2017026241A1 (ja) * 2015-08-07 2017-02-16 国立大学法人愛媛大学 質量分析を用いたｂ型肝炎ウイルスの測定方法
US11730761B2 (en) 2016-02-18 2023-08-22 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
AU2019267680C1 (en) 2018-05-10 2025-02-27 Melbourne Health Methods and compositions for the treatment of hepatitis b infection
EP3937976A4 (en) * 2019-03-12 2023-03-29 The General Hospital Corporation IMMUNOGENIC COMPOSITION IN A VERY DENSE NETWORK
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines
EP3964225A1 (en) * 2020-09-04 2022-03-09 Dompe' Farmaceutici S.P.A. Peptides endowed with angiogenic activity
BR112023003865A2 (pt) * 2020-09-04 2024-03-12 Dompe Farm Spa Peptídeos dotados de atividade angiogênica
US20250002926A1 (en) * 2021-11-12 2025-01-02 Regents Of The University Of Minnesota Compositions and methods for transcriptional activation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0500785B1 (en) 1989-11-03 2002-04-17 Immulogic Pharmaceutical Corporation A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor
WO1994024281A1 (en) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
FR2694938B1 (fr) * 1992-08-10 1996-11-15 Zagury Jean Francois Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
JP2002504322A (ja) 1998-02-20 2002-02-12 ザ ロックフェラー ユニバーシティー 樹状細胞に対するアポトーシス細胞介在抗原提示
US6080399A (en) * 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
US20020004041A1 (en) 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
BR0012556A (pt) * 1999-07-21 2002-07-02 Cornell Res Foundation Inc Genes e vacinas de ehrlichia canis
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
CA2384987A1 (en) * 1999-09-16 2001-03-22 Zycos Inc. Nucleic acids encoding polyepitope polypeptides
AU7867400A (en) * 1999-10-08 2001-04-23 Dendreon Corporation Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells
EP1252183B1 (en) * 1999-12-02 2006-05-24 Thromb-X N.V. Method for reducing the immunogenicity of staphylokinase by elimination of t-cell epitopes
AU2002218019A1 (en) * 2000-11-03 2002-05-15 Nexell Therapeutics Inc. Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
PL362412A1 (en) * 2001-02-06 2004-11-02 Merck Patent Gmbh Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
ES2456666T3 (es) * 2003-04-18 2014-04-23 Biotech Synergy, Inc. Péptidos antígenos HLA-A2 asociados a un tumor y composiciones

Also Published As

Publication number Publication date
EP2292642A1 (en) 2011-03-09
CA2528727A1 (en) 2004-12-16
JP2011173879A (ja) 2011-09-08
NZ544011A (en) 2009-02-28
US20070248584A1 (en) 2007-10-25
EP1638993A1 (en) 2006-03-29
JP2007537975A (ja) 2007-12-27
WO2004108753A1 (en) 2004-12-16
EP1638993A4 (en) 2007-05-09

Similar Documents

Publication Publication Date Title
BRPI0411127A (pt) composição de matéria para modulação de resposta imuno num sujeito a um antìgeno alvo e respectivos método de modulação, processo de produção de células de apresentação de antìgeno e método de tratamento e/ou profilaxia de doença ou condição associada à presença de antìgeno alvo de interesse
Keller et al. Crustacean hyperglycemic neuropeptides
Albert et al. Inhibition by calmodulin of calcium/phospholipid-dependent protein phosphorylation.
Brady et al. Nerve-specific enolase and creatine phosphokinase in axonal transport: soluble proteins and the axoplasmic matrix
Weigle Termination of acquired immunological tolerance to protein antigens following immunization with altered protein antigens
Nakashima et al. The folding type of a protein is relevant to the amino acid composition
BR112022000371A2 (pt) Anticorpos claudin18 e métodos de tratamento contra câncer
Hill et al. A chemical abnormality in haemoglobin G
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
Maurer Antigenicity of polypeptides (poly alpha amino acids) XIII. Immunological studies with synthetic polymers containing only D-or D-and L-α-amino acids
BR112018007960A2 (pt) conjugado, proteína pcrv, composição imunogênica, métodos de preparação de uma composição imunogênica, de tratamento e de produção de um bioconjugado, polinucleotídeo, vetor, célula hospedeira, e, bioconjugado.
BR112021018608A2 (pt) Anticorpos para claudina-6 e conjugados de fármaco
ATE6251T1 (de) Acylpeptide und pharmazeutische praeparate davon, sowie deren herstellung und verwendung.
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
de Oliveira Silva et al. Immunostimulatory activity of ConBr: a focus on splenocyte proliferation and proliferative cytokine secretion
Strominger et al. An evaluation of the significance of amino acid sequence homologies in human histocompatibility antigens (HLA‐A and HLA‐B) with immunoglobulins and other proteins, using relatively short sequences
Smith Nucleotide base coding and amino acid replacements in proteins
Holtzer et al. Changes in intermediate-sized filaments during myogenesis and neurogenesis
Okuda et al. An envelope-specific glycoprotein from Escherichia coli B
Aizawa et al. Limited chymotryptic digestion of bovine adrenal 190,000-Mr microtubule-associated protein and preparation of a 27,000-Mr fragment which stimulates microtubule assembly.
Butler Jr et al. A study of the cross-reactivity of antipurin-6-oyl serum with deoxyribonucleic acid (DNA)
BR112022016571A2 (pt) Métodos e composições para modular níveis de arginina em células imunes
GB1058828A (en) Process for the manufacture of artificial antigens
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos
Lan et al. Isolation and characterization of the major centipede allergen Sco m 5 from Scolopendra subspinipes mutilans

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: THE UNIVERSITY OF MELBOURNE (AU)

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020100102551/RJ DE 03/11/2010, E NECESSARIO APRESENTAR PROCURACAO OUTORGADA PELO CESSIONARIO.

B25B Requested transfer of rights rejected

Owner name: THE UNIVERSITY OF MELBOURNE (AU)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 20100102551/RJ DE 03/11/2010, POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2154, DE 17/04/2012.

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.